The aim of the present study was to define the potential relationship of xeroderma pigmentosum group D (XPD) Lys751Gln polymorphisms and the risk of leukemia.
INTRODUCTION
Leukemia, a common malignant disease of the hematopoietic system (Jiang et al., 2014) , can be classified on the basis of speed of disease progression and cell cytogenetics into four common subtypes: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) (Arber et al., 2016) . The etiological and mechanism of leukemogenesis are still unclear, though radiation, smoking, obesity and exposure to chemical carcinogens are considered high risk factors (Larsson and Wolk, 2008; Fircanis et al., 2014; Malagoli et al., 2016; Nikkila et al., 2016) . Nevertheless, only a small proportion of people exposed to these risk factors develop leukemia, suggesting that hereditary factors may play critical role in leukemia carcinogenesis (Li et al., 2016; Huang and Ovcharenko, 2017) .
Decreased efficiency of DNA repair is considered a crucial event in carcinogenesis (Hoeijmakers, 2001) . Recently, a series of studies revealed that reduced DNA repair, leading to chromosomal aberrations and genomic instability, is a major contributor to the pathogenesis of leukemia (Das-Gupta et al., 2000; Esposito and So, 2014) . Xeroderma pigmentosum group D (XPD) gene, also known as ERCC2, encodes a 5 -3 superfamily 2 (SF2) helicase that plays a key role in unwinding the DNA double helix around damaged DNA during nucleotide excision repair (NER) (Kuper et al., 2012; Constantinescu-Aruxandei et al., 2016) . Because of the biological significance of XPD, the XPD polymorphism has been extensively studied in different malignant diseases, such as pancreatic (Wu et al., 2017) , colorectal (Ni et al., 2014) and gallbladder (Srivastava et al., 2010) cancers.
Several studies revealed inconsistent results on the relationship between the XPD Lys751Gln polymorphism (SNP IDs: rs13181) and leukemia susceptibility. Some studies showed a clear trend of XPD Lys751Gln polymorphism with increased risk of leukemia (Juan et al., 2005; Ganster et al., 2009; Shi et al., 2011; Banescu et al., 2014 Banescu et al., , 2016 , while others displayed decreased risk of leukemia (Ozcan et al., 2011; Douzi et al., 2015) , and yet others suggested no association between this polymorphism and leukemia (Seedhouse et al., 2002; Allan et al., 2004; Matullo et al., 2006; Mehta et al., 2006; Pakakasama et al., 2007; Batar et al., 2009; Canalle et al., 2011; Ozdemir et al., 2012; Sorour et al., 2013; Dincer et al., 2015) . To evaluate more precisely the potential relationship between XPD Lys751Gln polymorphism and leukemia, we hereby report on a meta-analysis using all available published data.
MATERIALS AND METHODS

Search Strategies
A computerized search of Pubmed, Web of Science, EBSCO, the Cochrane Library and China National Knowledge Infrastructure (CNKI) up to March 2017 was conducted using the following search strategy: ("XPD" or "ERCC2" or "XPD"), and ("polymorphism" or "variant" or "mutation"), and "Leukemia." The search was restricted to English and Chinese written publications. A manual search of references of the retrieved articles and relevant reviews was also conducted. A flowchart of information pertaining to identification, screening, eligibility, and final datasets selected was constructed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Moher et al., 2009 ).
Inclusion and Exclusion Criteria
In this report, the studies that investigate the association between XPD Lys751Gln polymorphism and leukemia risk were included. The inclusion criteria were (1) case-control study design;
(2) available genotype information of the XPD Lys751Gln polymorphism; (3) evaluation of the XPD gene polymorphism and the risk of leukemia; and (4) the distribution of genotypes among the controls agreeing with Hardy-Weinberg equilibrium (HWE). Major criteria for exclusion were: (1) duplication of earlier publications (for studies using the same sample in different publications, only the most complete information was included following careful examination), (2) unpublished papers, dissertations, conference articles and reviews, (3) family based studies of pedigrees.
Data Extraction
Data from each eligible study were extracted into Excel including country of origin, ethnicity of each study population, age group (adult or childhood), subtypes of leukemia, genotyping method, numbers of cases and controls, numbers of cases and controls in the XPD Lys751Gln genotypes and results of the HWE test.
Study Quality Assessment
The quality of the included studies was assessed by two reviewers according to the Newcastle-Ottawa Scale (NOS) (Stang, 2010) , which is used to assess the quality of observational studies. Discrepancies were reported and settled by a third party. Three major aspects of study quality were scored: (1) selection of the study groups (0 ± 4 points); (2) determination of the exposure of interest in the studies (0 ± 3 points); and (3) the quality of the adjustment for confounding variables (0 ± 2 points). A study could be scored as a maximum of one star for each item numbered within the categories of Selection and Exposure, while at most two stars could be allocated to Comparability. A higher score represents improved greater quality of the study methodology. A score equal to or higher than 6 was considered to indicate high study quality.
Data Analysis
The combined odds ratios (ORs) and 95% confidence interval (CI) were used to evaluate the strength of the association with the risk of leukemia. Pooled ORs were performed for allelic comparison (a vs. A), dominant (aa + Aa vs. AA), recessive (aa vs. Aa + AA) and codominant (aa vs. AA and Aa vs. AA) models ('a' and ' A' represent the mutant allele and the wild-type allele, respectively). Heterogeneity among the included studies was assessed by I 2 statistic. A random-effects model or fixedeffects model was used to calculate pooled odds ratio (OR) in the presence or absence of heterogeneity, respectively. To detect possible sources of heterogeneity and potential difference among subgroups, meta-regression and subgroup analyses were carried out on stratification of different ethnicity, age group and subtypes of leukemia. The significance of the pooled OR was determined by Z-test, with p < 0.05 considered statistically significant. Publication bias was investigated using funnel plots and Egger's regression test. We also conducted sensitivity analysis to test the robustness of associations by sequentially omitting each of the included studies one at a time. All the data analysis was performed using the software STATA 14.0 (StataCorp, College Station, TX, United States) and Review Manager 5.3 (Cochrane Collaboration, Oxford, United Kingdom).
RESULTS
Literature Search and Study Characteristics
We used several search criteria to include or exclude reported studies on the relationship between XPD polymorphism and leukemia (Figure 1) . A total of 14 studies (2,757 cases and 4,768 controls) about XPD Lys751Gln polymorphism were included in the final evaluation ( Table 1) . Quality assessment of the individual studies showed that the Newcastle-Ottawa scale (NOS) score ranged from 6 to 8, indicating that the quality of methodology was generally good ( Table 2) .
Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia
Since significant heterogeneity was identified in recessive, homozygote and alleles models, random-effects model was used. The other genetic models were analysis by fixedeffects model. Overall, significant increase in leukemia risk was identified in dominant (Gln/Gln + Lys/Gln vs. Lys/Lys: I 2 = 24%, P < 0.001, Figure 2 ) and heterozygote models (Lys/Gln vs. Lys/Lys: I 2 = 0%, P < 0.001, Figure 3 ). No significant association was found in recessive (Gln/Gln vs. Lys/Gln + Lys/Lys: I 2 = 43%, P = 0.560, Figure 4 ) and homozygote (Gln/Gln vs. Lys/Lys: I 2 = 51%, P = 0.29, Figure 5 ) models. In addition, allele model showed a borderline significant increase in leukemia risk (Gln vs. Lys: I 2 = 50%, P = 0.05, Figure 6 ). Moderate heterogeneity (I 2 : 43-51%) AML, Acute myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia.
PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF MS, matrix assisted laser desorption/ionization time-of-flight mass spectrometry.
HWE P-value in the control group, P > 0.05 indicates that the participants in the control group met the HWE.
Frontiers in Genetics | www.frontiersin.org was found in the no-association model group. To explore the source of this heterogeneity, a meta-regression analysis was conducted. The results revealed that the heterogeneity was not associated with ethnicity, age, clinical subtype or detection method (p > 0.05 in all genetic models). We further explored the source of heterogeneity by removing one study each time. The results showed that the Matullo's study was one of the central sources of heterogeneity (its inclusion increased heterogeneity by 12-24%). No publication bias was found in any of the models. Sensitivity analysis suggested that with exception of the allele model, the results were stable and reliable.
Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Ethnicity
In Caucasian populations, a significant increase in leukemia risk was found in heterozygote model (Lys/Gln vs. Lys/Lys: I 2 = 0%, P = 0.02) and dominant models (Gln/Gln + Lys/Gln vs. Lys/Lys: I 2 = 14%, P = 0.02). No significant association was found in recessive (Gln/Gln vs. Lys/Gln + Lys/Lys: I 2 = 44%, P = 0.75), homozygote (Gln/Gln vs. Lys/Lys: I 2 = 55%, P = 0.32) and allele models (Gln vs. Lys: I 2 = 47%, P = 0.24) ( Table 3) . In African and Asian populations, subgroup analysis was unreliable as only two studies were available.
Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Age
In subgroup analysis by age group, one study was excluded as it lacked data on patients' age (Douzi et al., 2015) . Significant associations were consistently found in some genetic models of adult group (GlnGln + LysGln vs. LysLys: I 2 = 46.0%, P = 0.04; LysGln vs. LysLys: I 2 = 9%, P = 0.002), and in almost all models of childhood group (Gln vs. Lys: I 2 = 0%, P = 0.003; GlnGln + LysGln vs. LysLys: I 2 = 0%, P = 0.01; GlnGln vs. LysGln + LysLys: I 2 = 0%, P = 0.03; GlnGln vs. LysLys: I 2 = 0%, P = 0.009; LysGln vs. LysLys: I 2 = 0%, P = 0.04).
Moderate to higher heterogeneity (I 2 : 46-65%) was found in the no-association models of the adult group (Table 4) .
Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Subtype
In subgroup analysis by leukemia subtypes, one study was excluded as it lacked such data (Matullo et al., 2006) . Significant associations were found in almost all genetic models of acute leukemia (Gln vs. Lys: I 2 = 12%, P < 0.001; GlnGln + LysGln vs. LysLys: I 2 = 0%, P < 0.001; GlnGln vs. LysLys: I 2 = 14%, P = 0.02; LysGln vs. LysLys: I 2 = 0%, P = 0.003), and in some models of chronic disease (GlnGln + LysGln vs. LysLys: I 2 = 34%, P = 0.009; LysGln vs. LysLys: I 2 = 0%, P < 0.001) ( Table 5 ).
DISCUSSION
The NER pathway is a highly conserved DNA repair mechanism that removes bulky intra-strand adducts created by agents (Scharer, 2013) . Genetic polymorphism in DNA repair genes may cause variation in DNA repair capacity, which in turn can lead to cumulative genotoxic damage and increased susceptibility to cancer (Douzi et al., 2015) . As an important component of NER, XPD is an evolutionarily conserved ATP-dependent DNA helicase that plays an essential role in DNA repair (Kim et al., 2016) . Several studies suggested an increased risk of cancer in individuals with polymorphism in XPD or other NER pathway genes (Paszkowska-Szczur et al., 2013; He et al., 2016) . Moreover, several molecular epidemiological studies have found an association between XPD polymorphism and leukemia risk in diverse populations. However, the results were inconsistent and even contradictory. We therefore conducted a meta-analysis to globally evaluate the potential relationship between XPD polymorphism and leukemia.
Our results indicate that XPD Lys751Gln polymorphism significantly increase overall leukemia risk in dominant and heterozygote models, but not in allele model or homozygote model. The results suggest that heterozygous mutations but not homozygote mutations of XPD (Lys/Gln) may increase the genetic susceptibility of leukemia. This may be the result of a higher rates of heterozygous vs. homozygous mutations (the ratio between heterozygous and homozygous mutations is 2.27 ∼ 56 in control and 1.71 ∼ 29 in leukemia). Subgroup analysis by ethnicity showed the same result in Caucasian population. The exact mechanism for association between different tumors susceptibility and XPD Lys751Gln polymorphism is currently unknown. XPD is a 5 -3 superfamily 2 DNA helicase that opens damaged DNA for bulky lesion repair in NER. The interaction of C-terminal domain of XPD with the p44 helicase activator protein are critical for both helicase activity and stability of the TFIIH complex, which is essential for RNA polymerase (RNAP) II-mediated transcription initiation and the NER (Liu et al., 2008) . The XPD C-terminal Lys751Gln polymorphism may alter the structure of the C-terminal domain, hence blocking critical interaction with p44 and destructive TFIIH conformation, which subsequently reduce DNA repair activity (Lunn et al., 2000; Fan et al., 2008; Monaco et al., 2009 ). Furthermore, by stratifying the data by age and subtype of disease, we found that XPD Lys751Gln polymorphism significantly increased leukemia risk in almost all models of childhood and acute disease. The occurrence and development of leukemia appeared to be regulated by genetic and environmental factors. In children with acute leukemia, malignancy manifests with a short latency period, thus does not have enough exposure time to allow the initiation of a long carcinogenic process. Unlike children, adults usually develop cancer because of the cumulative effect of environmental exposure during his/her life (Brisson et al., 2015) . Thus, we speculate that genetic polymorphism is more important for childhood and acute leukemia.
Compared to previous reports Wu et al., 2014) , the present study has the following advantages: (1) it analyzed the association between XPD Lys751Gln polymorphism and acute leukemia, but also it association with chronic leukemia;
(2) A total of 14 studies (2,757 cases and 4,768 controls) were compiled in our research, thus increasing the statistical power of the analysis. (3) Strict literature inclusion and exclusion criteria were enforced, the Ozdemir's study was excluded from our analysis due to lack of discerning information between ALL and Burkitt lymphoma patients. However, our research also has some limitations: (1) The number of original studies included in the meta-analysis are relatively small, especially in the subgroup analysis. Future studies on ethnicity, age and subtype of leukemia are needed to further corroborate our findings. (2) Heterogeneity, which can greatly affect conclusions of meta-analysis, was high in some models. Our result showed that moderate or higher heterogeneity was found in some models, which showed no association with leukemia risk. The Matullo's study was a major source of this heterogeneity, probably due to the significant differences in number of cases and controls.
CONCLUSION
Our meta-analysis demonstrates that XPD Lys751Gln polymorphism significantly increases overall leukemia risk in dominant and heterozygote models, and that this polymorphism is significant associated with almost all genetic models of childhood and acute leukemia.
